Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.22, Iss.3, 2012-03, pp. : 335-339

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756)

By Deng Xianming S. Gray Nathanael

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 6, 2012-06 ,pp. : 709-713

Informa Healthcare

Access to resources Recommend Favorite

Chiral Kinase Inhibitors

Current Topics in Medicinal Chemistry, Vol. 11, Iss. 7, 2011-04 ,pp. : 800-809

Bentham Science Publishers

Access to resources Recommend Favorite

Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 1, 2014-01 ,pp. : 121-125

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2012003387, Gilead's ASK1 inhibitors

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 4, 2012-04 ,pp. : 455-459

Informa Healthcare

Access to resources Recommend Favorite

5-Lipoxygenase inhibitors: a patent evaluation (WO2011161615)

By Buscató Estel.la Proschak Ewgenij

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 7, 2012-07 ,pp. : 843-846

Informa Healthcare

Access to resources Recommend Favorite